Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy

Sajni Josson, Cynthia S. Anderson, Shian Ying Sung, Peter A S Johnstone, Hiroyuki Kubo, Chia Ling Hsieh, Rebecca Arnold, Murali Gururajan, Clayton Yates, Leland W K Chung

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

INTRODUCTION Recent studies demonstrated the importance of ADAM9 in prostate cancer relapse upon therapy. In this study, we determined the role of ADAM9 in the therapeutic resistance to radiation and chemotherapy. MATERIALS AND METHODS ADAM9 was either transiently or stably knocked down in C4-2 prostate cancer cells. The sensitivity of ADAM9 knockdown cells toward radiation and chemotherapeutic agents were determined. Additionally, the effects of ADAM9 knockdown on prostate cancer cell morphology, biochemical and functional alterations were accessed. RESULTS Both transient and stable knockdown of ADAM9 resulted in increased apoptosis and increased sensitivity to radiation. ADAM9 knockdown also increased prostate cancer sensitivity to several chemotherapeutic drugs. ADAM9 knockdown resulted in increased E-cadherin and altered integrin expression and underwent phenotypic epithelial transition. These were reflected by the morphological, biochemical, and functional alterations in the ADAM9 knockdown cells. CONCLUSIONS ADAM9 plays a crucial role in prostate cancer progression and therapeutic resistance in part by altering E-cadherin and integrin expression. ADAM9 is an important target for the consideration of treating prostate cancer patients who developed therapeutic resistance and disease relapse. Prostate

Original languageEnglish
Pages (from-to)232-240
Number of pages9
JournalProstate
Volume71
Issue number3
DOIs
Publication statusPublished - Feb 15 2011
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Radiation
Drug Therapy
Cadherins
Integrins
Recurrence
Disease Resistance
Radiation Tolerance
Therapeutics
Prostate
Apoptosis
Pharmaceutical Preparations

Keywords

  • ADAM9
  • E-cadherin
  • prostate cancer
  • radiation

ASJC Scopus subject areas

  • Urology
  • Oncology

Cite this

Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. / Josson, Sajni; Anderson, Cynthia S.; Sung, Shian Ying; Johnstone, Peter A S; Kubo, Hiroyuki; Hsieh, Chia Ling; Arnold, Rebecca; Gururajan, Murali; Yates, Clayton; Chung, Leland W K.

In: Prostate, Vol. 71, No. 3, 15.02.2011, p. 232-240.

Research output: Contribution to journalArticle

Josson, Sajni ; Anderson, Cynthia S. ; Sung, Shian Ying ; Johnstone, Peter A S ; Kubo, Hiroyuki ; Hsieh, Chia Ling ; Arnold, Rebecca ; Gururajan, Murali ; Yates, Clayton ; Chung, Leland W K. / Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. In: Prostate. 2011 ; Vol. 71, No. 3. pp. 232-240.
@article{b290ca42bae54e969ddd4527ccc72afd,
title = "Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy",
abstract = "INTRODUCTION Recent studies demonstrated the importance of ADAM9 in prostate cancer relapse upon therapy. In this study, we determined the role of ADAM9 in the therapeutic resistance to radiation and chemotherapy. MATERIALS AND METHODS ADAM9 was either transiently or stably knocked down in C4-2 prostate cancer cells. The sensitivity of ADAM9 knockdown cells toward radiation and chemotherapeutic agents were determined. Additionally, the effects of ADAM9 knockdown on prostate cancer cell morphology, biochemical and functional alterations were accessed. RESULTS Both transient and stable knockdown of ADAM9 resulted in increased apoptosis and increased sensitivity to radiation. ADAM9 knockdown also increased prostate cancer sensitivity to several chemotherapeutic drugs. ADAM9 knockdown resulted in increased E-cadherin and altered integrin expression and underwent phenotypic epithelial transition. These were reflected by the morphological, biochemical, and functional alterations in the ADAM9 knockdown cells. CONCLUSIONS ADAM9 plays a crucial role in prostate cancer progression and therapeutic resistance in part by altering E-cadherin and integrin expression. ADAM9 is an important target for the consideration of treating prostate cancer patients who developed therapeutic resistance and disease relapse. Prostate",
keywords = "ADAM9, E-cadherin, prostate cancer, radiation",
author = "Sajni Josson and Anderson, {Cynthia S.} and Sung, {Shian Ying} and Johnstone, {Peter A S} and Hiroyuki Kubo and Hsieh, {Chia Ling} and Rebecca Arnold and Murali Gururajan and Clayton Yates and Chung, {Leland W K}",
year = "2011",
month = "2",
day = "15",
doi = "10.1002/pros.21237",
language = "English",
volume = "71",
pages = "232--240",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy

AU - Josson, Sajni

AU - Anderson, Cynthia S.

AU - Sung, Shian Ying

AU - Johnstone, Peter A S

AU - Kubo, Hiroyuki

AU - Hsieh, Chia Ling

AU - Arnold, Rebecca

AU - Gururajan, Murali

AU - Yates, Clayton

AU - Chung, Leland W K

PY - 2011/2/15

Y1 - 2011/2/15

N2 - INTRODUCTION Recent studies demonstrated the importance of ADAM9 in prostate cancer relapse upon therapy. In this study, we determined the role of ADAM9 in the therapeutic resistance to radiation and chemotherapy. MATERIALS AND METHODS ADAM9 was either transiently or stably knocked down in C4-2 prostate cancer cells. The sensitivity of ADAM9 knockdown cells toward radiation and chemotherapeutic agents were determined. Additionally, the effects of ADAM9 knockdown on prostate cancer cell morphology, biochemical and functional alterations were accessed. RESULTS Both transient and stable knockdown of ADAM9 resulted in increased apoptosis and increased sensitivity to radiation. ADAM9 knockdown also increased prostate cancer sensitivity to several chemotherapeutic drugs. ADAM9 knockdown resulted in increased E-cadherin and altered integrin expression and underwent phenotypic epithelial transition. These were reflected by the morphological, biochemical, and functional alterations in the ADAM9 knockdown cells. CONCLUSIONS ADAM9 plays a crucial role in prostate cancer progression and therapeutic resistance in part by altering E-cadherin and integrin expression. ADAM9 is an important target for the consideration of treating prostate cancer patients who developed therapeutic resistance and disease relapse. Prostate

AB - INTRODUCTION Recent studies demonstrated the importance of ADAM9 in prostate cancer relapse upon therapy. In this study, we determined the role of ADAM9 in the therapeutic resistance to radiation and chemotherapy. MATERIALS AND METHODS ADAM9 was either transiently or stably knocked down in C4-2 prostate cancer cells. The sensitivity of ADAM9 knockdown cells toward radiation and chemotherapeutic agents were determined. Additionally, the effects of ADAM9 knockdown on prostate cancer cell morphology, biochemical and functional alterations were accessed. RESULTS Both transient and stable knockdown of ADAM9 resulted in increased apoptosis and increased sensitivity to radiation. ADAM9 knockdown also increased prostate cancer sensitivity to several chemotherapeutic drugs. ADAM9 knockdown resulted in increased E-cadherin and altered integrin expression and underwent phenotypic epithelial transition. These were reflected by the morphological, biochemical, and functional alterations in the ADAM9 knockdown cells. CONCLUSIONS ADAM9 plays a crucial role in prostate cancer progression and therapeutic resistance in part by altering E-cadherin and integrin expression. ADAM9 is an important target for the consideration of treating prostate cancer patients who developed therapeutic resistance and disease relapse. Prostate

KW - ADAM9

KW - E-cadherin

KW - prostate cancer

KW - radiation

UR - http://www.scopus.com/inward/record.url?scp=78951469330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78951469330&partnerID=8YFLogxK

U2 - 10.1002/pros.21237

DO - 10.1002/pros.21237

M3 - Article

VL - 71

SP - 232

EP - 240

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 3

ER -